Biosimilars

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

A new partnership promises up to 22% savings for employers by integrating deep pharmacy expertise, tackling one of healthcare's most complex challenges.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

Reimbursements are falling and costs are rising, but top allergy practices are boosting revenue by 22%. A new report reveals their data-driven secrets.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.